CSF2RA antibody (FITC)

Catalog No. ABIN2661473

Product Details anti-CSF2RA Antibody (FITC)

Target: CSF2RA (Colony Stimulating Factor 2 Receptor, Alpha, Low-Affinity (Granulocyte-Macrophage) (CSF2RA))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CSF2RA antibody is conjugated to FITC

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC), Flow Cytometry (FACS), Immunofluorescence (IF), Functional Studies (Func), Intracellular Flow Cytometry (ICFC)

Purification: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

Clone: 4H1

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CSF2RA

Target: CSF2RA (Colony Stimulating Factor 2 Receptor, Alpha, Low-Affinity (Granulocyte-Macrophage) (CSF2RA))

Alternative Name: CD116 (CSF2RA Products)

Background: CD116 is a 70-85 kD α chain of the GM-CSF receptor. It combines with CDw131 β chain to form the high affinity GM-CSF receptor. A soluble form of CD116, which binds GM-CSF with a relatively low affinity, has been identified. In addition, an alternatively spliced form of CD116 with an altered cytoplasmic tail has been described. CD116 is expressed on various myeloid cells including monocytes, macrophages, neutrophils, eosinophils, dendritic cells and their precursors, fibroblasts, and endothelial cells. CD116 is expressed on myeloid leukemias, osteogenic sarcoma cell lines, osteoblast-like cells and breast and lung carcinoma cell lines.

Pathways: JAK-STAT Signaling